-
1
-
2
Genomic landscape of lymphatic malformations: a case series and response to the PI3Kα inhibitor alpelisib in an N-of-1 clinical trial
Published 2022-07-01“…This work has been funded in part by the NCI Cancer Center Support Grants (CCSG; P30) to the University of Arizona Cancer Center (CA023074), the University of New Mexico Comprehensive Cancer Center (CA118100), and the Rutgers Cancer Institute of New Jersey (CA072720). B.K.M. was supported by National Science Foundation via Graduate Research Fellowship DGE-1143953. …”
Get full text
Article -
3
-
4
Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling
Published 2021-11-01“…Anderson Cancer Center and P30CA072720 the Rutgers Cancer Institute of New Jersey). This research has also been supported in part by grants from the National Science Foundation Grant DMS-1930583 (ZW, VC), the National Institutes of Health (NIH) 1R01CA253865 (ZW, VC), 1U01CA196403 (ZW, VC), 1U01CA213759 (ZW, VC), 1R01CA226537 (ZW, RP, WA, VC), 1R01CA222007 (ZW, VC), U54CA210181 (ZW, VC), and the University of Texas System STARS Award (VC). …”
Get full text
Article -
5
-
6
Loss of the BRCA1-PALB2 interaction accelerates p53-associated tumor development in mice
Published 2022-05-01Get full text
Article -
7
-
8
Next Generation Sequencing As an Aid to Diagnosis and Treatment of an Unusual Pediatric Brain Cancer
Published 2014-07-01Get full text
Article -
9
-
10
Integrated metabolic and genetic analysis reveals distinct features of human differentiated thyroid cancer
Published 2023-06-01Get full text
Article